Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (341-350 of 463) with videos related to

Pageof 47
Sort By:
Digestive Diseases and Sciences|July 15, 2021
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching AnalysisEun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, et al.
Gastroenterology|July 17, 2007
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006Michael Clark, Jean-Frederic Colombel, Brian C Feagan, et al.
Journal of Crohn'S & Colitis|October 9, 2012
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementAxel Dignass, James O Lindsay, Andreas Sturm, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI TrialWilliam J Sandborn, Rory Rebuck, Yuhua Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2024
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative ColitisSilvio Danese, Michael E Rothenberg, Jeremy J Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2022
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction TreatmentEdward V Loftus, Jean-Frederic Colombel, Ken Takeuchi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 15, 2019
Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel DiseasesJordan E Axelrad, Ahmad Bazarbashi, James Zhou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2015
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled TrialsJennifer L Jones, Gilaad G Kaplan, Laurent Peyrin-Biroulet, et al.
Pageof 47

Showing results (341-350 of 463) with videos related to

Sort By:
Pageof 47
Digestive Diseases and Sciences|July 15, 2021
Comparison of 1-Year Colectomy Risk Between the US and Korean Patients with Acute Severe Ulcerative Colitis: A Propensity Score Matching AnalysisEun Soo Kim, Kyeong Ok Kim, Byung Ik Jang, et al.
Gastroenterology|July 17, 2007
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006Michael Clark, Jean-Frederic Colombel, Brian C Feagan, et al.
Journal of Crohn'S & Colitis|October 9, 2012
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current managementAxel Dignass, James O Lindsay, Andreas Sturm, et al.
The Lancet. Gastroenterology & Hepatology|November 19, 2021
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 studySilvio Danese, Jean-Frederic Colombel, Milan Lukas, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2021
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn's Disease: The IM-UNITI TrialWilliam J Sandborn, Rory Rebuck, Yuhua Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 18, 2024
A Randomized Phase II Study of Efmarodocokin Alfa, an interleukin-22 Agonist, Versus Vedolizumab in Patients With Ulcerative ColitisSilvio Danese, Michael E Rothenberg, Jeremy J Lim, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 5, 2021
COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United StatesManasi Agrawal, Erica J Brenner, Joyce Wing Yan Mak, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 4, 2022
Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction TreatmentEdward V Loftus, Jean-Frederic Colombel, Ken Takeuchi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 15, 2019
Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel DiseasesJordan E Axelrad, Ahmad Bazarbashi, James Zhou, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 5, 2015
Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled TrialsJennifer L Jones, Gilaad G Kaplan, Laurent Peyrin-Biroulet, et al.
Pageof 47